203 related articles for article (PubMed ID: 33719954)
21. Inhibition of Ras prenylation: a novel approach to cancer chemotherapy.
Sebti SM; Hamilton AD
Pharmacol Ther; 1997; 74(1):103-14. PubMed ID: 9336018
[TBL] [Abstract][Full Text] [Related]
22. Ras farnesyltransferase inhibitors suppress the phenotype resulting from an activated ras mutation in Caenorhabditis elegans.
Hara M; Han M
Proc Natl Acad Sci U S A; 1995 Apr; 92(8):3333-7. PubMed ID: 7536929
[TBL] [Abstract][Full Text] [Related]
23. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts.
Sun J; Qian Y; Hamilton AD; Sebti SM
Oncogene; 1998 Mar; 16(11):1467-73. PubMed ID: 9525745
[TBL] [Abstract][Full Text] [Related]
24. Probing the hydrophobic pocket of farnesyltransferase: aromatic substitution of CAAX peptidomimetics leads to highly potent inhibitors.
Qian Y; Marugan JJ; Fossum RD; Vogt A; Sebti SM; Hamilton AD
Bioorg Med Chem; 1999 Dec; 7(12):3011-24. PubMed ID: 10658608
[TBL] [Abstract][Full Text] [Related]
25. Farnesyltransferase and geranylgeranyltransferase I: structures, mechanism, inhibitors and molecular modeling.
Shen M; Pan P; Li Y; Li D; Yu H; Hou T
Drug Discov Today; 2015 Feb; 20(2):267-76. PubMed ID: 25450772
[TBL] [Abstract][Full Text] [Related]
26. Farnesylation and proteolysis are sequential, but distinct steps in the CaaX box modification pathway.
Farh L; Mitchell DA; Deschenes RJ
Arch Biochem Biophys; 1995 Apr; 318(1):113-21. PubMed ID: 7726551
[TBL] [Abstract][Full Text] [Related]
27. Farnesyltransferase inhibitors: a detailed chemical view on an elusive biological problem.
Sousa SF; Fernandes PA; Ramos MJ
Curr Med Chem; 2008; 15(15):1478-92. PubMed ID: 18537624
[TBL] [Abstract][Full Text] [Related]
28. Time-dependent inhibition of protein farnesyltransferase by a benzodiazepine peptide mimetic.
Roskoski R; Ritchie PA
Biochemistry; 2001 Aug; 40(31):9329-35. PubMed ID: 11478901
[TBL] [Abstract][Full Text] [Related]
29. [Correlation between inhibitory effect of Manumycin on human hepatoma cancer cell HepG2 and Ras signal transduction pathway].
Zhou JM; Pan QC; Yang XP; Liu ZC; Liao DF; Fu LW; Liang YJ
Ai Zheng; 2002 Apr; 21(4):364-8. PubMed ID: 12452012
[TBL] [Abstract][Full Text] [Related]
30. Manumycin and gliotoxin derivative KT7595 block Ras farnesylation and cell growth but do not disturb lamin farnesylation and localization in human tumour cells.
Nagase T; Kawata S; Tamura S; Matsuda Y; Inui Y; Yamasaki E; Ishiguro H; Ito T; Miyagawa J; Mitsui H; Yamamoto K; Kinoshita M; Matsuzawa Y
Br J Cancer; 1997; 76(8):1001-10. PubMed ID: 9376258
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of Ras prenylation: a signaling target for novel anti-cancer drug design.
Lerner EC; Hamilton AD; Sebti SM
Anticancer Drug Des; 1997 Jun; 12(4):229-38. PubMed ID: 9199657
[TBL] [Abstract][Full Text] [Related]
32. A mutant form of human protein farnesyltransferase exhibits increased resistance to farnesyltransferase inhibitors.
Del Villar K; Urano J; Guo L; Tamanoi F
J Biol Chem; 1999 Sep; 274(38):27010-7. PubMed ID: 10480914
[TBL] [Abstract][Full Text] [Related]
33. Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes.
Lerner EC; Qian Y; Blaskovich MA; Fossum RD; Vogt A; Sun J; Cox AD; Der CJ; Hamilton AD; Sebti SM
J Biol Chem; 1995 Nov; 270(45):26802-6. PubMed ID: 7592920
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of corneal inflammation by the topical use of Ras farnesyltransferase inhibitors: selective inhibition of macrophage localization.
Sonoda K; Sakamoto T; Yoshikawa H; Ashizuka S; Ohshima Y; Kishihara K; Nomoto K; Ishibashi T; Inomata H
Invest Ophthalmol Vis Sci; 1998 Nov; 39(12):2245-51. PubMed ID: 9804132
[TBL] [Abstract][Full Text] [Related]
35. Inactivation of farnesyltransferase and geranylgeranyltransferase I by caspase-3: cleavage of the common alpha subunit during apoptosis.
Kim KW; Chung HH; Chung CW; Kim IK; Miura M; Wang S; Zhu H; Moon KD; Rha GB; Park JH; Jo DG; Woo HN; Song YH; Kim BJ; Yuan J; Jung YK
Oncogene; 2001 Jan; 20(3):358-66. PubMed ID: 11313965
[TBL] [Abstract][Full Text] [Related]
36. Enhanced antiproliferative and apoptotic response of HT-29 adenocarcinoma cells to combination of photoactivated hypericin and farnesyltransferase inhibitor manumycin A.
Sačková V; Kuliková L; Kello M; Uhrinová I; Fedoročko P
Int J Mol Sci; 2011; 12(12):8388-405. PubMed ID: 22272079
[TBL] [Abstract][Full Text] [Related]
37. Efficient farnesylation of an extended C-terminal C(
Blanden MJ; Suazo KF; Hildebrandt ER; Hardgrove DS; Patel M; Saunders WP; Distefano MD; Schmidt WK; Hougland JL
J Biol Chem; 2018 Feb; 293(8):2770-2785. PubMed ID: 29282289
[TBL] [Abstract][Full Text] [Related]
38. High affinity for farnesyltransferase and alternative prenylation contribute individually to K-Ras4B resistance to farnesyltransferase inhibitors.
Fiordalisi JJ; Johnson RL; Weinbaum CA; Sakabe K; Chen Z; Casey PJ; Cox AD
J Biol Chem; 2003 Oct; 278(43):41718-27. PubMed ID: 12882980
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of protein farnesylation enhances the chemotherapeutic efficacy of the novel geranylgeranyltransferase inhibitor BAL9611 in human colon cancer cells.
Di Paolo A; Danesi R; Caputo S; Macchia M; Lastella M; Boggi U; Mosca F; Marchetti A; Del Tacca M
Br J Cancer; 2001 Jun; 84(11):1535-43. PubMed ID: 11384105
[TBL] [Abstract][Full Text] [Related]
40. Farnesyltransferase inhibitors as anticancer agents: current status.
Zhu K; Hamilton AD; Sebti SM
Curr Opin Investig Drugs; 2003 Dec; 4(12):1428-35. PubMed ID: 14763128
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
